Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 3/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11287487 | 0.82 | GRIK1 (0.47) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL9952145 | 0.76 | SLC1A2 (0.37) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL9282670 | 0.72 | SLC1A2 (0.47) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL1312180 | 0.72 | GRIK1 (0.50) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL2179588 | 0.72 | GRIK1 (0.50) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL5185206 | 0.72 | CA2 (0.41) | SLC1A2SLC1A1SLC1A3CA2MAPK1 | |
| SCHEMBL19411253 | 0.71 | GRIK1 (0.35) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL221495 | 0.71 | SLC1A2 (0.46) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL16290200 | 0.71 | CA2 (0.47) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL3079688 | 0.69 | SLC1A2 (0.44) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630441-A1 | SYNTHETIC PEPTIDE FOR USE IN AN IMMUNOMOLECULAR ASSAY | bioMérieux (FR) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121128-A1 | SYNTHETIC PEPTIDE FOR USE IN AN IMMUNOMOLECULAR ASSAY | bioMérieux (FR) | 2024-06-13 | — | — | WO | disclosed |
| EP-4382534-A1 | SYNTHETIC PEPTIDE FOR USE IN AN IMMUNOMOLECULAR ASSAY | BIOMÉRIEUX (FR) | 2024-06-12 | — | — | EP | disclosed |
| US-9629934-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | DYAX CORP. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9446155-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | BRACCO SUISSE SA (CH) | 2016-09-20 | — | — | US | disclosed |
| US-9408926-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | BRACCO SUISSE S.A. (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2015-12-31 | — | — | US | disclosed |
| US-9056138-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2015-06-16 | — | — | US | disclosed |
| CN-104428006-A | Covalently linked antigen-antibody conjugates | HOFFMANN LA ROCHE | 2015-03-18 | — | — | CN | disclosed |
| US-20140286864-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | BRACCO SUISSE SA (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | BRACCO SUISSE SA (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050100963-A1 | Multimeric protein comprising endothelial growth factor (VEGF) and kinase domain region (KDR) for use in detection, prevention and treatment of cell proliferative, virral and infectious disorders | DYAX CORPORATION (US) | 2005-05-12 | — | — | US | disclosed |
| US-20050027105-A9 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | BRACCO SUISSE SA (CH) | 2005-02-03 | — | — | US | disclosed |
| EP-1482987-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2004-12-08 | — | — | EP | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
| WO-2004065621-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004064595-A2 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL BV (NL) | 2004-08-05 | — | — | WO | disclosed |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2004-01-29 | — | — | US | disclosed |
| WO-2003084574-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL BV (NL) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003074005-A2 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | LDHB, FPGS, MTHFD2 | SLC1A2 706/4885SLC1A1 399/4885SLC1A3 264/4885 |
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | SLC1A2 4782/4885SLC1A1 4375/4885SLC1A3 4257/4885 |
| US-20050027105-A9 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | SLC1A2 4607/4885SLC1A1 4361/4885SLC1A3 4316/4885 |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | CD47, BCR, CD44 | SLC1A2 4782/4885SLC1A1 4375/4885SLC1A3 4257/4885 |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | SLC1A2 4607/4885SLC1A1 4361/4885SLC1A3 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.